Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCLC 2023 | Highlights in ADCs from WCLC 2023

Amin Nassar, MD, Yale Cancer Centre, New Haven, CT, shares his highlights from the 2023 World Conference on Lung Cancer 2023. The HERHENA-Lung01 trial (NCT04619004) generated promising results in the use of patritumab deruxtecan in patients with EGFR-mutant non-small cell lung cancer (NSCLC) who had received prior EGFR tyrosine kinase inhibitor therapy and platinum-based chemotherapy. Results demonstrated that the patients had an improvement in duration of response and the disease control rate. Dr Nassar also comments on new data in the mesothelioma setting that challenges the status of surgery as a standard of care treatment for early-stage disease. This interview took place at the WCLC 2023 in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.